Hypoglycemic hydroxyurea derivatives
AssigneePfizer Inc.
InventorsSteven W. Goldstein, Ruth E. McDermott
Life of this patent
Estimating the term…
Abstract
There are disclosed preparative processes and hypoglycemic compounds of the formula ##STR1## wherein R is hydrogen or C1 to C3 alkyl; R.sup.1 and R.sup.2 are taken together and are carbonyl; or R.sup.1 and R.sup.2 are taken separately, wherein R.sup.1 is hydrogen or R.sup.4 and R.sup.2 is--COR.sup.5 and COOR.sup.5 ; R.sup.3, R.sup.4 and R.sup.5 are each independently C1 to C9 alkyl, C3 to C7 cycloalkyl, phenyl, naphthyl, furyl, benzofuryl or thienyl or one of said groups mono- or disubstituted with C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 alkoxy-carbonyl, trifluoromethyl, fluoro or chloro; and n is 0 or 1; or pharmaceutically acceptable cationic salts thereof.
Claims6
A compound of the formula ##STR8## wherein R is hydrogen or C1 to C3 alkyl;
- R.sup.1 and R.sup.2 are together and are carbonyl;
- R.sup.3 is C1 to C9 alkyl, C3 to C7 cycloalkyl, phenyl, naphthyl, furyl, benzofuryl or thienyl or one of said groups mono- or disubstituted with C1 to C3 alkyl, C1 to C.sub.3 alkoxy, C1 to C3 alkoxycarbonyl, trifluoromethyl, fluoro or chloro;
- and
- n is 0 or 1;
- or
- a pharmaceutically acceptable cationic salt thereof.
Dependencies are inferred from the claim text.